medline.ch Gynäkologie Mammae

	The impact of different pathological diagnostic criteria on the prognosis of malignant phyllodes tumors of the breast. Virchows Arch Cai L, Yue M, Shang J, Jia Y, Sun X, Liu C, Wang X, Wu S, Li J, Liu Y. PMID: 41746333 [PubMed - as supplied by publisher]
	Spatial Patterns of Breast Cancer Risk Associated with Industrial and Environmental Pollutants: A Scoping Review. Toxics Nahal D, Hoffpauir A, Kinariwala K, Tetteh P, Orenge F, Patel A, Ghalib A, Northeim K. PMID: 41745813 [PubMed]
	Dynamic Contrast-Enhanced MRI Kinetic Curve-Driven Parametric Radiomics for Predicting Breast Cancer Molecular Subtypes: A Multicenter and Interpretable Study. Tomography Wang T, Gong J, Wang S, Sun S, Zhou J, Lin L, Zhang D, You C, Gu Y. PMID: 41745704 [PubMed - in process]
	Automated Radiological Report Generation from Breast Ultrasound Images Using Vision and Language Transformers. J Imaging Khatoon S, Mahmood A. PMID: 41745433 [PubMed]
	Reproductive Toxicity of Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: A Case Report with a Literature Review. Diseases Tanase-Damian C, Antone NZ, Paun DL, Tanase I, Achima. PMID: 41745089 [PubMed]
	Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer. Curr Oncol Guo S, Addison CL. PMID: 41744893 [PubMed - in process]
	Estrogen Receptor-Low Positive (ER-Low) Breast Cancer: A Unique Clinical and Pathological Entity. Curr Oncol Faa G, Lai E, Ziranu P, Pretta A, Tiwari E, Dessì M, Solinas C, Saba G, Loi F, Codipietro C, Graziano S, Ottelio L, Dessena M, Coghe F, Suri JS, Saba L, Scartozzi M. PMID: 41744886 [PubMed - in process]
	Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC). Curr Oncol Median MD, Antone NZ, Volov, Mazilu L, Negru , Curc, Ni, P, Ungureanu A, Lupu V, Oprean CM. PMID: 41744884 [PubMed - in process]
	Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025. Curr Oncol Sehdev S, Joy AA, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Gelmon KA, Jerzak KJ, Kumar A, Laing K, LeVasseur N, Simmons C, Webster M, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada. PMID: 41744876 [PubMed - in process]
	Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. Curr Oncol Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada. PMID: 41744870 [PubMed - in process]
	Trop2-Based Antibody-Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy. Curr Oncol Li T, Zhang T, Dang Y, Lin Y, Li X, Ling X. PMID: 41744856 [PubMed - in process]
	DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential. Curr Oncol Niture S, Thotala D, Jaboin J, Seneviratne D. PMID: 41744846 [PubMed - in process]
	Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2- Women with Metastatic Breast Cancer: Results from PALCAN Study. Curr Oncol Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, Cheung WY, Sharma A, On PV, Feugère G, Lupichuk S. PMID: 41744845 [PubMed - in process]
	High-Risk Benign Breast Lesions: An Ontario Health (Cancer Care Ontario) Recommendations Report. Curr Oncol Eisen A, Bane A, Causer P, Cordeiro E, Fienberg S, Kornecki A, Kulkarni A, Hong NL, Mancuso T, Muradali D, Nofech-Mozes S, Roberts A, Shaheen R, Courtney S, Grove R, Brackstone M. PMID: 41744831 [PubMed - in process]
	Expression Patterns and Clinical Relevance of HSP70 and Metallothionein in Triple-Negative and Luminal A Breast Cancer: A Croatian Cohort Study. Cells Bili, Guli, Grebi, Toki, Avirovi, Savi, Marinovi, Juri, Brozni. PMID: 41744793 [PubMed - in process]
	The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion. Cells Khachikian A, Ho M, Bonavida B. PMID: 41744762 [PubMed - in process]
	Tactile-Sensation Imaging System for Assessing Material Inclusions in Breast Tumor Detection. Biosensors (Basel) Nairuz T, Lee JH. PMID: 41744719 [PubMed - in process]
	Revealing the Spatial-Molecular Fingerprint of BMP4 Expression in Breast Cancer Using ToF-SIMS and Multiple Instance Learning. Anal Chem Gardner W, Borg J, Mouchemore KA, Chi LH, Bell C, Nickless D, Yeo B, Bamford SE, Winkler DA, Muir BW, Anderson RL, Pigram PJ. PMID: 41744150 [PubMed - as supplied by publisher]
	Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer. Front Oncol Frontiers Editorial Office. PMID: 41743960 [PubMed]
	Resilient Sinkhorn-Based Optimal Transport Late Fusion Framework for Breast Cancer Diagnosis. Cancer Inform Asiedu Asare M, Acquah I, Yeboah BA, Owusu E. PMID: 41743692 [PubMed]

Artikel 1 - 20 / 214970

Seite 1 von 10749

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung